Glenmark receives ANDA approval for Olopatadine Hydrochloride ophthalmic solution USP, 0.2%
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
FlexiTubes will showcase range of eco-friendly and innovative tube options
Nipaguard SCE Vita delivers comprehensive antimicrobial protection for personal care formulations
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
This expanded partnership helps Evonik to streamline its distribution model in Asia Pacific
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Vidya will spark conversations around less discussed and important aspects of health, including intimate care and sleep issues
Subscribe To Our Newsletter & Stay Updated